Does Rallies show live market data for NPCE?

Rallies combines live market context with ticker research for NPCE, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.

NPCE (Neuropace, Inc. Common Stock) Stock Analysis

Neuropace, Inc. Common Stock (NPCE) is a publicly traded Healthcare sector company. As of May 21, 2026, NPCE trades at $16.29 with a market cap of $545.16M and a P/E ratio of -24.63. NPCE moved +2.43% today. Year to date, NPCE is +2.59%; over the trailing twelve months it is -9.56%. Its 52-week range spans $5.45 to $19.60. Analyst consensus is strong buy with an average price target of $19.75. Rallies surfaces NPCE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the latest NPCE stock research?

Neuropace, Inc. Common Stock (NPCE) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. NPCE moved +2.43% today. Analyst consensus is strong buy.

NPCE Key Metrics

Key financial metrics for NPCE
Metric	Value
Price	$16.29
Market Cap	$545.16M
P/E Ratio	-24.63
EPS	$-0.65
Dividend Yield	0.00%
52-Week High	$19.60
52-Week Low	$5.45
Volume	164.07K
Avg Volume	0
Revenue (TTM)	$99.53M
Net Income	$-21.57M
Gross Margin	78.29%

Latest NPCE News

NeuroPace Q1 Sales Up 19.5%, Guidance Raised to 21–23% with $20 Price Target — May 15, 2026
NeuroPace narrows Q1 loss to $0.13 per share, beats estimates and ups revenue outlook — May 12, 2026
NeuroPace Shares Surge 6.3% to $18.12 on Heavy Volume, Q1 Revenue Seen $21.6M — May 11, 2026
NeuroPace Boosts Medicare RNS Reimbursement 44%, Forecasts $98M–$100M 2026 Revenue — Mar 10, 2026
NeuroPace Q4 Loss Narrows to $0.08, Revenues Jump 23.8% to $26.6M — Mar 3, 2026

Recent NPCE Insider Trades

Morrell Martha sold 25.00K (~$399.25K) on Dec 15, 2025.
ORBIMED ADVISORS LLC sold 134.14K (~$2.12M) on May 14, 2025.
ORBIMED ADVISORS LLC sold 34.00K (~$541.96K) on May 14, 2025.

NPCE Analyst Consensus

4 analysts cover NPCE: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.75.

Common questions about NPCE

What can I research for NPCE on Rallies?: Neuropace, Inc. Common Stock (NPCE) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. NPCE moved +2.43% today. Analyst consensus is strong buy.
Does Rallies show live market data for NPCE?: Rallies combines live market context with ticker research for NPCE, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.